Class Acceleration Corp. (CLAS)

TORONTO--(BUSINESS WIRE)--A Settlement has been reached in the global class action (the “Class Action”) against Aphria and certain of its former officers and directors (“Individual Defendants”) announces Rochon Genova LLP. The Settlement requires Court approval at an upcoming hearing. The Class Action alleges that, between January 29, 2018 and December 3, 2018, Aphria and the Individual Defendants made public misrepresentations to the capital markets, including in an Aphria Prospectus Offering.

BOCA RATON, Fla., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Saxena White P.A. issues this notice to update and replace a prior press release issued by Saxena White on December 11, 2024. Plaintiff City of Fort Lauderdale Police and Firefighters' Retirement System has filed a Notice of Scrivener's Error with the United States District Court for the Middle District of Tennessee, which attaches a corrected Class Action complaint correcting a typographical error that inadvertently defined the Class Period as beginning on February 8, 2020, whereas the Class Action complaint alleges that the Class Period begins on February 28, 2020. The prior press release issued by Saxena White on December 11, 2024 contained the same typographical error. The Class Action asserts claims on behalf of all persons and entities that purchased or otherwise acquired Acadia Healthcare Company, Inc. securities between February 28, 2020 and October 30, 2024, inclusive. The full, updated press release follows:

BOCA RATON, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Saxena White P.A. has filed a securities fraud class action lawsuit (the “Class Action”) in the United States District Court for the Southern District of New York against Dentsply Sirona Inc. (“Dentsply” or the “Company”) (NASDAQ: XRAY) and certain of its executive officers (collectively, “Defendants”). The Class Action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and U.S. Securities and Exchange Commission (“SEC”) Rule 10b-5 promulgated thereunder on behalf of all persons and entities that purchased Dentsply common stock between December 1, 2022 and November 6, 2024, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The Class Action filed by Saxena White is captioned North Collier Fire Control and Rescue District Firefighters' Retirement Plan v. Dentsply Sirona Inc., et al., No. 24-cv-9083 (S.D.N.Y.).

ODD DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Oddity Tech Ltd. Investors to Secure Counsel Before Important September 17 Deadline in Securities Class Action - ODD September 17, 2024 10:45 AM EDT | Source: The Rosen Law Firm PA New York, New York--(Newsfile Corp. - September 17, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Oddity Tech Ltd. (NASDAQ: ODD) between July 19, 2023 and May 20, 2024, both dates inclusive (the "Class Period"), of the important September 17, 2024 lead plaintiff deadline.SO WHAT: If you purchased Oddity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.WHAT TO DO NEXT: To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 17, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Oddity overstated its AI technology and capabilities, and/or the extent to which this technology drove Oddity's sales; (2) Oddity's repeat purchase rates and revenues were, at least in part, derived from unsustainable and deceptive sales and advertising practices; (3) Oddity downplayed the true scope and severity of ongoing civil litigation against Oddity and/or its subsidiaries; and (4) as a result, Oddity's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.Attorney Advertising. Prior results do not guarantee a similar outcome.-------------------------------Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/223615 SOURCE: The Rosen Law Firm PA Learn more about Bill C-18 and how it will affect Canadian users when viewing news online.

MGNX DEADLINE NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages MacroGenics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 24 Deadline in Securities Class Action - MGNX September 17, 2024 11:53 AM EDT | Source: The Rosen Law Firm PA New York, New York--(Newsfile Corp. - September 17, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"), of the important September 24, 2024 lead plaintiff deadline.SO WHAT: If you purchased stock or sold puts of MacroGenics during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.WHAT TO DO NEXT: To join the MacroGenics class action, go to https://rosenlegal.com/submit-form/?case_id=27488 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 24, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements concerning Macrogenic's TAMARACK Phase 2 study of its drug vobramitamab duocarmazine (vobra duo) in patients with resistant prostate cancer. Specifically, the Complaint alleges that defendants' statements created a materially misleading impression concerning the safety profile of vobra duo and the totality of the Phase 2 TAMARACK study data. When the true details entered the market, the lawsuit claims that investors suffered damages.To join the MacroGenics class action, go to https://rosenlegal.com/submit-form/?case_id=27488 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.Attorney Advertising. Prior results do not guarantee a similar outcome.-------------------------------Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/223617 SOURCE: The Rosen Law Firm PA Learn more about Bill C-18 and how it will affect Canadian users when viewing news online.

ROSEN, A TOP RANKED LAW FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important May 28 Deadline in Securities Class Action - BLUE May 19, 2024 12:41 PM EDT | Source: The Rosen Law Firm PA New York, New York--(Newsfile Corp. - May 19, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of bluebird bio, Inc. (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, both dates inclusive (the "Class Period"), of the important May 28, 2024 lead plaintiff deadline.SO WHAT: If you purchased bluebird common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.WHAT TO DO NEXT: To join the bluebird class action, go to https://rosenlegal.com/submit-form/?case_id=23717 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 28, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements. Specifically, defendants created the false impression that: (1) bluebird could obtain Federal Drug Administration ("FDA") approval for lovo-cel, a gene therapy for sickle cell patients, without any black box warnings for haematological malignancies; (2) bluebird would be granted a priority review voucher by the FDA and in turn sell it in order to strengthen bluebird's financial position for the lovo-cel launch; (3) as a result, bluebird had significantly overstated Lyfgenia's clinical and/or commercial prospects; and (4) therefore, bluebird's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.To join the bluebird class action, go to https://rosenlegal.com/submit-form/?case_id=23717 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.Attorney Advertising. Prior results do not guarantee a similar outcome.-------------------------------Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/209688 SOURCE: The Rosen Law Firm PA Learn more about Bill C-18 and how it will affect Canadian users when viewing news online.

WOODSIDE, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Class Acceleration Corp. (NYSE: CLAS, CLAS.U, CLAS.W) (the “Company”) today announced that it received a notice from the New York Stock Exchange (the "NYSE") indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the "Q1 2021 Form 10-Q") with the Securities and Exchange Commission (the "SEC"). The notice has no immediate effect on the listing of the Company's stock on the NYSE.